Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Paul Lesueur, Justine Lequesne, Jean-Michel Grellard, Audrey Dugué, Elodie Coquan, Pierre-Emmanuel Brachet, Julien Geffrelot, William Kao, Evelyne Emery, David Hassanein Berro, Laurent Castera, Nicolas Goardon, Joëlle Lacroix, Marie Lange, Aurélie Capel, Alexandra Leconte, Benoit Andre, Angélique Léger, Anaïs Lelaidier, Bénédicte Clarisse, Dinu Stefan

ABSTRACT

BACKGROUND: Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development of new radiosensitizer is crucial to improve the patient outcomes. Pre-clinical data showed that Poly (ADP-ribose) polymerase inhibitors (PARPi) could be considered as a promising class of radiosensitizer. The aim of this study is to evaluate Olaparib, a PARPi, as radiosensitizing agent, combined with the Stupp protocol, namely temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) in first line treatment of partially or non-resected GBM. METHODS: The OLA-TMZ-RTE-01 study is a multicenter non-randomized phase I/IIa trial including unresectable or partially resectable GBM patients, from 18 to 70 years old. A two-step dose-escalation phase I design will first determine the recommended phase 2 dose (RP2D) of olaparib, delivered concomitantly with TMZ plus conventional irradiation for 6 weeks and as single agent for 4 weeks (radiotherapy period), and second, the RP2D of olaparib combined with adjuvant TMZ (maintenance period). Phase IIa will assess the 18-month overall survival (OS) of this combination. In both phase I and IIa separately considered, the progression-free survival, the objective response rate, the neurocognitive functions of patients, emotional disorders among caregivers, the survival without toxicity, degradation nor progression, the complications onset and the morphologic and functional MRI (magnetic resonance imaging) parameters will be also assessed as secondary objectives. Ancillary objectives will explore alteration of the DNA repair pathways on biopsy tumor, proton magnetic resonance spectroscopy parameters to differentiate tumor relapse and radionecrosis, and an expanded cognition evaluation. Up to 79 patients will be enrolled: 30 patients in the phase I and 49 patients in the phase IIa. DISCUSSION: Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. Ancillary studies will help to identify genetic biomarkers predictive of PARPi efficacy as radiosensitizer. TRIAL REGISTRATION: NCT03212742 , registered June, 7, 2017. Protocol version: Version 2.2 dated from 2017/08/18. More... »

PAGES

198

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-019-5413-y

DOI

http://dx.doi.org/10.1186/s12885-019-5413-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112527602

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30832617


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Caen Basse-Normandie", 
          "id": "https://www.grid.ac/institutes/grid.412043.0", 
          "name": [
            "Radiation Oncology Department, Centre Fran\u00e7ois Baclesse, 3 avenue du G\u00e9n\u00e9ral Harris, F-14076, Caen, France", 
            "Normandy university, University of Caen Basse Normandie, 14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lesueur", 
        "givenName": "Paul", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lequesne", 
        "givenName": "Justine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grellard", 
        "givenName": "Jean-Michel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dugu\u00e9", 
        "givenName": "Audrey", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France", 
            "Medical Oncology Department, Centre Fran\u00e7ois Baclesse, 14076, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coquan", 
        "givenName": "Elodie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France", 
            "Medical Oncology Department, Centre Fran\u00e7ois Baclesse, 14076, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brachet", 
        "givenName": "Pierre-Emmanuel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Radiation Oncology Department, Centre Fran\u00e7ois Baclesse, 3 avenue du G\u00e9n\u00e9ral Harris, F-14076, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Geffrelot", 
        "givenName": "Julien", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Radiation Oncology Department, Centre Fran\u00e7ois Baclesse, 3 avenue du G\u00e9n\u00e9ral Harris, F-14076, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kao", 
        "givenName": "William", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Caen", 
          "id": "https://www.grid.ac/institutes/grid.411149.8", 
          "name": [
            "Normandy university, University of Caen Basse Normandie, 14000, Caen, France", 
            "Neurosurgery Department, CHU de Caen, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Emery", 
        "givenName": "Evelyne", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Caen", 
          "id": "https://www.grid.ac/institutes/grid.411149.8", 
          "name": [
            "Normandy university, University of Caen Basse Normandie, 14000, Caen, France", 
            "Neurosurgery Department, CHU de Caen, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berro", 
        "givenName": "David Hassanein", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Genetic and oncology biology Department, Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castera", 
        "givenName": "Laurent", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Genetic and oncology biology Department, Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goardon", 
        "givenName": "Nicolas", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Radiology Department, Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lacroix", 
        "givenName": "Jo\u00eblle", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Caen Basse-Normandie", 
          "id": "https://www.grid.ac/institutes/grid.412043.0", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France", 
            "UNICAEN, INSERM, U1086 Anticipe, Normandie University, 14076, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lange", 
        "givenName": "Marie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Capel", 
        "givenName": "Aur\u00e9lie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leconte", 
        "givenName": "Alexandra", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "IT department, Centre Fran\u00e7ois Baclesse, F-14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Andre", 
        "givenName": "Benoit", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Pharmacy, Centre Fran\u00e7ois Baclesse, F-14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00e9ger", 
        "givenName": "Ang\u00e9lique", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Northwest Data Center (CTD-CNO), Centre Fran\u00e7ois Baclesse, F-14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lelaidier", 
        "givenName": "Ana\u00efs", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Clinical Research Department Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarisse", 
        "givenName": "B\u00e9n\u00e9dicte", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Radiation Oncology Department, Centre Fran\u00e7ois Baclesse, 3 avenue du G\u00e9n\u00e9ral Harris, F-14076, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stefan", 
        "givenName": "Dinu", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.yexcr.2014.07.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012545919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0360-3016(93)90203-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012786896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2288-3-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013392713", 
          "https://doi.org/10.1186/1471-2288-3-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2008.07.031", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020200449"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00401-016-1545-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021788062", 
          "https://doi.org/10.1007/s00401-016-1545-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-14-3790", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022199924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bimj.201300261", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026534482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2010.08.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035348638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036499081", 
          "https://doi.org/10.1038/nature03443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036499081", 
          "https://doi.org/10.1038/nature03443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03445", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039649759", 
          "https://doi.org/10.1038/nature03445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03445", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039649759", 
          "https://doi.org/10.1038/nature03445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-1223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041711258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.3541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.5491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050620950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa043330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052112015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.2001.95.2.0190", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071100026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.2001.95.2.0190", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071100026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.2001.95.2.0190", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071100026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.2003.99.3.0467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071100893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.2003.99.3.0467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071100893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.2003.99.3.0467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071100893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.2003.99.3.0467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071100893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.20.5.1375", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083941991"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4149/neo_2017_502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085941054"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4149/neo_2017_502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085941054"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.19079", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092090714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-018-22022-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101130683", 
          "https://doi.org/10.1038/s41598-018-22022-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-018-22022-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101130683", 
          "https://doi.org/10.1038/s41598-018-22022-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2018.36.15_suppl.2018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106714624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.15_suppl.2022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106846091"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development of new radiosensitizer is crucial to improve the patient outcomes. Pre-clinical data showed that Poly (ADP-ribose) polymerase inhibitors (PARPi) could be considered as a promising class of radiosensitizer. The aim of this study is to evaluate Olaparib, a PARPi, as radiosensitizing agent, combined with the Stupp protocol, namely temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) in first line treatment of partially or non-resected GBM.\nMETHODS: The OLA-TMZ-RTE-01 study is a multicenter non-randomized phase I/IIa trial including unresectable or partially resectable GBM patients, from 18 to 70\u2009years old. A two-step dose-escalation phase I design will first determine the recommended phase 2 dose (RP2D) of olaparib, delivered concomitantly with TMZ plus conventional irradiation for 6\u2009weeks and as single agent for 4\u2009weeks (radiotherapy period), and second, the RP2D of olaparib combined with adjuvant TMZ (maintenance period). Phase IIa will assess the 18-month overall survival (OS) of this combination. In both phase I and IIa separately considered, the progression-free survival, the objective response rate, the neurocognitive functions of patients, emotional disorders among caregivers, the survival without toxicity, degradation nor progression, the complications onset and the morphologic and functional MRI (magnetic resonance imaging) parameters will be also assessed as secondary objectives. Ancillary objectives will explore alteration of the DNA repair pathways on biopsy tumor, proton magnetic resonance spectroscopy parameters to differentiate tumor relapse and radionecrosis, and an expanded cognition evaluation. Up to 79 patients will be enrolled: 30 patients in the phase I and 49 patients in the phase IIa.\nDISCUSSION: Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. Ancillary studies will help to identify genetic biomarkers predictive of PARPi efficacy as radiosensitizer.\nTRIAL REGISTRATION: NCT03212742 , registered June, 7, 2017. Protocol version: Version 2.2 dated from 2017/08/18.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-019-5413-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol", 
    "pagination": "198", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1c6129a9d68cf2bc57389b9a94d102339f77623bd10591c3e4b77b5f05344437"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30832617"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-019-5413-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112527602"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-019-5413-y", 
      "https://app.dimensions.ai/details/publication/pub.1112527602"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78938_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-019-5413-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5413-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5413-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5413-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5413-y'


 

This table displays all metadata directly associated to this object as RDF triples.

275 TRIPLES      21 PREDICATES      51 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-019-5413-y schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nc3f3cd89b82a438d887a617c50ffa6f6
4 schema:citation sg:pub.10.1007/s00401-016-1545-1
5 sg:pub.10.1038/nature03443
6 sg:pub.10.1038/nature03445
7 sg:pub.10.1038/s41598-018-22022-4
8 sg:pub.10.1186/1471-2288-3-6
9 https://doi.org/10.1002/bimj.201300261
10 https://doi.org/10.1002/sim.5491
11 https://doi.org/10.1016/0360-3016(93)90203-8
12 https://doi.org/10.1016/j.ijrobp.2008.07.031
13 https://doi.org/10.1016/j.radonc.2010.08.020
14 https://doi.org/10.1016/j.yexcr.2014.07.003
15 https://doi.org/10.1056/nejmoa043330
16 https://doi.org/10.1158/0008-5472.can-14-3790
17 https://doi.org/10.1158/1078-0432.ccr-08-1223
18 https://doi.org/10.1200/jco.2002.20.5.1375
19 https://doi.org/10.1200/jco.2009.26.3541
20 https://doi.org/10.1200/jco.2017.35.15_suppl.2022
21 https://doi.org/10.1200/jco.2018.36.15_suppl.2018
22 https://doi.org/10.18632/oncotarget.19079
23 https://doi.org/10.3171/jns.2001.95.2.0190
24 https://doi.org/10.3171/jns.2003.99.3.0467
25 https://doi.org/10.4149/neo_2017_502
26 schema:datePublished 2019-12
27 schema:datePublishedReg 2019-12-01
28 schema:description BACKGROUND: Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development of new radiosensitizer is crucial to improve the patient outcomes. Pre-clinical data showed that Poly (ADP-ribose) polymerase inhibitors (PARPi) could be considered as a promising class of radiosensitizer. The aim of this study is to evaluate Olaparib, a PARPi, as radiosensitizing agent, combined with the Stupp protocol, namely temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) in first line treatment of partially or non-resected GBM. METHODS: The OLA-TMZ-RTE-01 study is a multicenter non-randomized phase I/IIa trial including unresectable or partially resectable GBM patients, from 18 to 70 years old. A two-step dose-escalation phase I design will first determine the recommended phase 2 dose (RP2D) of olaparib, delivered concomitantly with TMZ plus conventional irradiation for 6 weeks and as single agent for 4 weeks (radiotherapy period), and second, the RP2D of olaparib combined with adjuvant TMZ (maintenance period). Phase IIa will assess the 18-month overall survival (OS) of this combination. In both phase I and IIa separately considered, the progression-free survival, the objective response rate, the neurocognitive functions of patients, emotional disorders among caregivers, the survival without toxicity, degradation nor progression, the complications onset and the morphologic and functional MRI (magnetic resonance imaging) parameters will be also assessed as secondary objectives. Ancillary objectives will explore alteration of the DNA repair pathways on biopsy tumor, proton magnetic resonance spectroscopy parameters to differentiate tumor relapse and radionecrosis, and an expanded cognition evaluation. Up to 79 patients will be enrolled: 30 patients in the phase I and 49 patients in the phase IIa. DISCUSSION: Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. Ancillary studies will help to identify genetic biomarkers predictive of PARPi efficacy as radiosensitizer. TRIAL REGISTRATION: NCT03212742 , registered June, 7, 2017. Protocol version: Version 2.2 dated from 2017/08/18.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree true
32 schema:isPartOf N96da82193c2846878b06f78fb4c98860
33 Ne473e784fead4a6b9e2820df4aa53d38
34 sg:journal.1024632
35 schema:name Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
36 schema:pagination 198
37 schema:productId N09008ead12d44c3ab7bde273caa9604f
38 N18994f1a79f74bb58c742d860fe85917
39 N606bce38e0374561966b1a3febb5c85d
40 N78d27a6c83bb4162849fd520296aa247
41 Nfd5e511b7293480288df238702854d58
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112527602
43 https://doi.org/10.1186/s12885-019-5413-y
44 schema:sdDatePublished 2019-04-11T13:18
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher Nd28525f1f1f14c05bc43a98e7d039e0c
47 schema:url https://link.springer.com/10.1186%2Fs12885-019-5413-y
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N0596b64f608d4bb493632dc02ea094b8 rdf:first N21edc0f78570475bb17ec0f2c9049cb7
52 rdf:rest N7a91d6d04dd5499d89e8bbbe7dc90bfe
53 N08fabedaca094e87b1af076bab326fbc schema:affiliation https://www.grid.ac/institutes/grid.476192.f
54 schema:familyName Coquan
55 schema:givenName Elodie
56 rdf:type schema:Person
57 N09008ead12d44c3ab7bde273caa9604f schema:name pubmed_id
58 schema:value 30832617
59 rdf:type schema:PropertyValue
60 N094e6eb53a5b464dabe90fba2ecfe0df schema:affiliation https://www.grid.ac/institutes/grid.476192.f
61 schema:familyName Lelaidier
62 schema:givenName Anaïs
63 rdf:type schema:Person
64 N0b1527d2be8a4416afa89c947f3f3b27 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
65 schema:familyName Capel
66 schema:givenName Aurélie
67 rdf:type schema:Person
68 N0e25337602b243758afbc819d64814ff rdf:first N59a3f3e3aa114528979d25131d23736e
69 rdf:rest N6b8b3c4e25ce40768700a4e9411e9fa3
70 N181b21f3a8cf44e38abb52b6ab4b28a3 rdf:first N8adbfdf9f9f64ba5ab1da33b3188c566
71 rdf:rest N702781253a7244089424962750a1010c
72 N18994f1a79f74bb58c742d860fe85917 schema:name nlm_unique_id
73 schema:value 100967800
74 rdf:type schema:PropertyValue
75 N21edc0f78570475bb17ec0f2c9049cb7 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
76 schema:familyName Dugué
77 schema:givenName Audrey
78 rdf:type schema:Person
79 N266f090573e34fbfb8995a3be761d6e9 rdf:first N0b1527d2be8a4416afa89c947f3f3b27
80 rdf:rest N0e25337602b243758afbc819d64814ff
81 N287934c187414834a467e5b0e2745f03 rdf:first N5caf395c42c94845acd6d36c493d65d1
82 rdf:rest N181b21f3a8cf44e38abb52b6ab4b28a3
83 N33430fc43f254f8bb1947160c34a6be7 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
84 schema:familyName Lequesne
85 schema:givenName Justine
86 rdf:type schema:Person
87 N36dd20ac6321441895a3ddc7b7d0f7c1 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
88 schema:familyName Grellard
89 schema:givenName Jean-Michel
90 rdf:type schema:Person
91 N497bca143554432fae711f1a297147c6 rdf:first N9c7978f6b4a84f5c80ef3935cdceb542
92 rdf:rest N63261528742b4b9896995a5dfb31d3b4
93 N4c67d3be66d049ffa5a2da91666d8818 rdf:first N933f56d522ce464ab997c2370d89c4af
94 rdf:rest N8e1b106a19984c6e966309df998c7d6a
95 N583f18385873471598bdb4d190abd610 rdf:first Nb4bb9bb80fb84ac1803da5cd2e476886
96 rdf:rest N287934c187414834a467e5b0e2745f03
97 N59a3f3e3aa114528979d25131d23736e schema:affiliation https://www.grid.ac/institutes/grid.476192.f
98 schema:familyName Leconte
99 schema:givenName Alexandra
100 rdf:type schema:Person
101 N5ca7a4cceae94974b2ddd4ae3441f2a6 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
102 schema:familyName Kao
103 schema:givenName William
104 rdf:type schema:Person
105 N5caf395c42c94845acd6d36c493d65d1 schema:affiliation https://www.grid.ac/institutes/grid.411149.8
106 schema:familyName Berro
107 schema:givenName David Hassanein
108 rdf:type schema:Person
109 N606bce38e0374561966b1a3febb5c85d schema:name doi
110 schema:value 10.1186/s12885-019-5413-y
111 rdf:type schema:PropertyValue
112 N63261528742b4b9896995a5dfb31d3b4 rdf:first N094e6eb53a5b464dabe90fba2ecfe0df
113 rdf:rest Nd28d27bf5283469991a2c4274d0a1ec1
114 N6474b21b72b54b97bfe7f3fb0255f14b schema:affiliation https://www.grid.ac/institutes/grid.412043.0
115 schema:familyName Lesueur
116 schema:givenName Paul
117 rdf:type schema:Person
118 N64ffe506954742c08c90ed16b3e5e888 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
119 schema:familyName Lacroix
120 schema:givenName Joëlle
121 rdf:type schema:Person
122 N6b8b3c4e25ce40768700a4e9411e9fa3 rdf:first Na3577b71c679434191f0aead7c70eea9
123 rdf:rest N497bca143554432fae711f1a297147c6
124 N6d010e472dcc413ebe9274ced091387a rdf:first N9913056c9821429b9f8ca2b2cb794b40
125 rdf:rest rdf:nil
126 N6e09eacf34d1493b95c04daa1cfbebb5 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
127 schema:familyName Clarisse
128 schema:givenName Bénédicte
129 rdf:type schema:Person
130 N702781253a7244089424962750a1010c rdf:first Na8e1dc32429b44e4a75818fe8fa4ef2b
131 rdf:rest Nb5b2353e82e94956a3108c8a000ca4b9
132 N78d27a6c83bb4162849fd520296aa247 schema:name readcube_id
133 schema:value 1c6129a9d68cf2bc57389b9a94d102339f77623bd10591c3e4b77b5f05344437
134 rdf:type schema:PropertyValue
135 N7a91d6d04dd5499d89e8bbbe7dc90bfe rdf:first N08fabedaca094e87b1af076bab326fbc
136 rdf:rest Nf00abaeee80d4a649999225ca9a1afc6
137 N814ef1edab8f4c80bd426756213daa52 rdf:first Nc35836da891d4b13b12b827bfe655dde
138 rdf:rest N266f090573e34fbfb8995a3be761d6e9
139 N8adbfdf9f9f64ba5ab1da33b3188c566 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
140 schema:familyName Castera
141 schema:givenName Laurent
142 rdf:type schema:Person
143 N8e1b106a19984c6e966309df998c7d6a rdf:first N5ca7a4cceae94974b2ddd4ae3441f2a6
144 rdf:rest N583f18385873471598bdb4d190abd610
145 N933f56d522ce464ab997c2370d89c4af schema:affiliation https://www.grid.ac/institutes/grid.476192.f
146 schema:familyName Geffrelot
147 schema:givenName Julien
148 rdf:type schema:Person
149 N96da82193c2846878b06f78fb4c98860 schema:issueNumber 1
150 rdf:type schema:PublicationIssue
151 N9913056c9821429b9f8ca2b2cb794b40 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
152 schema:familyName Stefan
153 schema:givenName Dinu
154 rdf:type schema:Person
155 N9c7978f6b4a84f5c80ef3935cdceb542 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
156 schema:familyName Léger
157 schema:givenName Angélique
158 rdf:type schema:Person
159 Na3577b71c679434191f0aead7c70eea9 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
160 schema:familyName Andre
161 schema:givenName Benoit
162 rdf:type schema:Person
163 Na8e1dc32429b44e4a75818fe8fa4ef2b schema:affiliation https://www.grid.ac/institutes/grid.476192.f
164 schema:familyName Goardon
165 schema:givenName Nicolas
166 rdf:type schema:Person
167 Na925e6cf1b5d454ba5effa4a47e0e567 rdf:first N33430fc43f254f8bb1947160c34a6be7
168 rdf:rest Nd65b115d9f1d4203916bad694b00281f
169 Nb4bb9bb80fb84ac1803da5cd2e476886 schema:affiliation https://www.grid.ac/institutes/grid.411149.8
170 schema:familyName Emery
171 schema:givenName Evelyne
172 rdf:type schema:Person
173 Nb5b2353e82e94956a3108c8a000ca4b9 rdf:first N64ffe506954742c08c90ed16b3e5e888
174 rdf:rest N814ef1edab8f4c80bd426756213daa52
175 Nc35836da891d4b13b12b827bfe655dde schema:affiliation https://www.grid.ac/institutes/grid.412043.0
176 schema:familyName Lange
177 schema:givenName Marie
178 rdf:type schema:Person
179 Nc3f3cd89b82a438d887a617c50ffa6f6 rdf:first N6474b21b72b54b97bfe7f3fb0255f14b
180 rdf:rest Na925e6cf1b5d454ba5effa4a47e0e567
181 Nd28525f1f1f14c05bc43a98e7d039e0c schema:name Springer Nature - SN SciGraph project
182 rdf:type schema:Organization
183 Nd28d27bf5283469991a2c4274d0a1ec1 rdf:first N6e09eacf34d1493b95c04daa1cfbebb5
184 rdf:rest N6d010e472dcc413ebe9274ced091387a
185 Nd65b115d9f1d4203916bad694b00281f rdf:first N36dd20ac6321441895a3ddc7b7d0f7c1
186 rdf:rest N0596b64f608d4bb493632dc02ea094b8
187 Ne473e784fead4a6b9e2820df4aa53d38 schema:volumeNumber 19
188 rdf:type schema:PublicationVolume
189 Ne922b2d68ec44155af5e3d36029725df schema:affiliation https://www.grid.ac/institutes/grid.476192.f
190 schema:familyName Brachet
191 schema:givenName Pierre-Emmanuel
192 rdf:type schema:Person
193 Nf00abaeee80d4a649999225ca9a1afc6 rdf:first Ne922b2d68ec44155af5e3d36029725df
194 rdf:rest N4c67d3be66d049ffa5a2da91666d8818
195 Nfd5e511b7293480288df238702854d58 schema:name dimensions_id
196 schema:value pub.1112527602
197 rdf:type schema:PropertyValue
198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical and Health Sciences
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
202 schema:name Oncology and Carcinogenesis
203 rdf:type schema:DefinedTerm
204 sg:journal.1024632 schema:issn 1471-2407
205 schema:name BMC Cancer
206 rdf:type schema:Periodical
207 sg:pub.10.1007/s00401-016-1545-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021788062
208 https://doi.org/10.1007/s00401-016-1545-1
209 rdf:type schema:CreativeWork
210 sg:pub.10.1038/nature03443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036499081
211 https://doi.org/10.1038/nature03443
212 rdf:type schema:CreativeWork
213 sg:pub.10.1038/nature03445 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039649759
214 https://doi.org/10.1038/nature03445
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/s41598-018-22022-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101130683
217 https://doi.org/10.1038/s41598-018-22022-4
218 rdf:type schema:CreativeWork
219 sg:pub.10.1186/1471-2288-3-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013392713
220 https://doi.org/10.1186/1471-2288-3-6
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1002/bimj.201300261 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026534482
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1002/sim.5491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050620950
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1016/0360-3016(93)90203-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012786896
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1016/j.ijrobp.2008.07.031 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020200449
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1016/j.radonc.2010.08.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035348638
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1016/j.yexcr.2014.07.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012545919
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1056/nejmoa043330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052112015
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1158/0008-5472.can-14-3790 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022199924
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1158/1078-0432.ccr-08-1223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041711258
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2002.20.5.1375 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083941991
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2017.35.15_suppl.2022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106846091
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2018.36.15_suppl.2018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106714624
247 rdf:type schema:CreativeWork
248 https://doi.org/10.18632/oncotarget.19079 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092090714
249 rdf:type schema:CreativeWork
250 https://doi.org/10.3171/jns.2001.95.2.0190 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071100026
251 rdf:type schema:CreativeWork
252 https://doi.org/10.3171/jns.2003.99.3.0467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071100893
253 rdf:type schema:CreativeWork
254 https://doi.org/10.4149/neo_2017_502 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085941054
255 rdf:type schema:CreativeWork
256 https://www.grid.ac/institutes/grid.411149.8 schema:alternateName Centre Hospitalier Universitaire de Caen
257 schema:name Neurosurgery Department, CHU de Caen, Caen, France
258 Normandy university, University of Caen Basse Normandie, 14000, Caen, France
259 rdf:type schema:Organization
260 https://www.grid.ac/institutes/grid.412043.0 schema:alternateName Université de Caen Basse-Normandie
261 schema:name Clinical Research Department Centre François Baclesse, Caen, France
262 Normandy university, University of Caen Basse Normandie, 14000, Caen, France
263 Radiation Oncology Department, Centre François Baclesse, 3 avenue du Général Harris, F-14076, Caen, France
264 UNICAEN, INSERM, U1086 Anticipe, Normandie University, 14076, Caen, France
265 rdf:type schema:Organization
266 https://www.grid.ac/institutes/grid.476192.f schema:alternateName Centre Franois Baclesse
267 schema:name Clinical Research Department Centre François Baclesse, Caen, France
268 Genetic and oncology biology Department, Centre François Baclesse, Caen, France
269 IT department, Centre François Baclesse, F-14000, Caen, France
270 Medical Oncology Department, Centre François Baclesse, 14076, Caen, France
271 Northwest Data Center (CTD-CNO), Centre François Baclesse, F-14000, Caen, France
272 Pharmacy, Centre François Baclesse, F-14000, Caen, France
273 Radiation Oncology Department, Centre François Baclesse, 3 avenue du Général Harris, F-14076, Caen, France
274 Radiology Department, Centre François Baclesse, Caen, France
275 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...